Archive · 27 Jul 2026
Viyash Scientific Reports Strong FY26 Performance
Viyash Scientific has released its FY26 annual report, showing successful integration of its subsidiaries and strong profitability.
Appco Pharma (US) is a major earnings driver, contributing nearly 40% of the consolidated profit.
The company has improved its business mix by focusing on complex generics and differentiated products.
It has also invested in manufacturing and R&D, particularly in the Companion Animal franchise.
Revenue quality improved with PLI incentives and licensing income.
The company's governance remains comfortable, with no material related-party transactions involving key management personnel-controlled entities.
However, Dr. Haribabu Bodepudi's high remuneration and transactions with Piramal Pharma Ltd and Aterna Labs Pvt Ltd are notable.
Analysts retain a 'Buy' rating with a target price of ₹290.
Viyash Scientific's FY26 annual report highlights successful integration of subsidiaries and strong profitability.
Appco Pharma (US) contributes nearly 40% of consolidated profit, showing a sharp turnaround in profitability.
The company is shifting its Human Formulations portfolio towards complex generics and differentiated products.
Manufacturing investments continued with the gross block increasing to ₹1,820 crore.
Governance remains comfortable with no material related-party transactions involving KMP-controlled entities.
- Who
- Viyash Scientific and its subsidiaries, including Appco Pharma (US), Alivira Animal Health, and Viyash LifeSciences
- What
- Successful integration of subsidiaries, strong profitability, and strategic investments in manufacturing and R&D
- When
- FY26 annual report published on July 27, 2026
- Where
- Global operations with a focus on the US market for Appco Pharma
- Why
- To report financial performance, highlight strategic initiatives, and provide insights for investors
Investor Perspective
Corporate Governance Perspective
Profitability and Growth
Investor Perspective
Investors see the successful integration of subsidiaries and strong profitability as positive indicators for future growth and stock performance.
Corporate Governance Perspective
Corporate governance experts focus on the high remuneration of Dr. Haribabu Bodepudi and transactions with related entities as areas of concern.
- Current Market Price (CMP)
- ₹259.85
- Target Price
- ₹290
- Consolidated Profit Contribution by Appco Pharma (US)
- 40%
- PLI Incentives and Licensing Income
- ₹60.90 crore
- Gross Block
- ₹1,820 crore
- Dr. Haribabu Bodepudi's Remuneration
- ₹78 crore